Eptifibatide Research Peptide (GP IIb/IIIa Inhibitor) Supplier — UPOR Biotech
Eptifibatide (CAS 188627-80-7) — a synthetic cyclic heptapeptide based on the KGD (Lys-Gly-Asp) recognition motif of barbourin, a disintegrin from the pigmy rattlesnake. A reversible glycoprotein IIb/IIIa (αIIbβ3 integrin) antagonist that blocks fibrinogen cross-linking of platelets and inhibits platelet aggregation. Supplied as lyophilized powder. Research Grade (RUO) — from UPOR Biotech.
Request a QuoteProduct Overview
Eptifibatide (CAS 188627-80-7, C₃₅H₄₉N₁₁O₉S₂, MW 831.96 g/mol) is a synthetic cyclic heptapeptide based on the KGD (Lys-Gly-Asp) recognition motif of barbourin, a disintegrin isolated from the venom of the southeastern pigmy rattlesnake (Sistrurus miliarius barbouri). The peptide contains a single intramolecular disulfide bond formed between the mercaptopropionyl (Mpr) residue at position 1 and the C-terminal cysteine, creating a rigid cyclic scaffold (sequence Mpr–Har–Gly–Asp–Trp–Pro–Cys–NH₂, where Har is homoarginine). Eptifibatide is a reversible antagonist of the platelet glycoprotein IIb/IIIa (αIIbβ3 integrin) receptor — the KGD motif mimics the RGD sequence of fibrinogen, blocking fibrinogen and von Willebrand factor cross-linking of platelets and thereby inhibiting platelet aggregation, the final common pathway of thrombus formation. Supplied as a white to off-white lyophilized powder with ≥98% HPLC purity.
As a specialized research peptide supplier, UPOR Biotech provides high-purity eptifibatide for thrombosis, hemostasis, platelet biology, and cardiovascular pharmacology research. Eptifibatide is the active principle of the FDA-approved drug Integrilin, indicated for acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) — making it a widely used reference compound for antiplatelet and GP IIb/IIIa mechanism studies. This product is supplied for research purposes only: Research Use Only (RUO) — not for human diagnostic or therapeutic use. Certifications include ISO 9001, cGMP, and FDA facility registration. Available in 1 mg, 5 mg, 10 mg, and 50 mg vials with full analytical documentation (COA, HPLC, MS, endotoxin).
Eptifibatide vs Tirofiban / Abciximab — KGD-Motif Peptide vs RGD-Mimetic vs Monoclonal Antibody
The three classes of GP IIb/IIIa inhibitors differ fundamentally in structure and pharmacology. Eptifibatide is a cyclic KGD-motif heptapeptide (barbourin-derived) — a reversible, competitive antagonist with rapid onset and offset (short plasma half-life, ~2.5 hours) and platelet function recovery within hours of discontinuation. Tirofiban is a non-peptide RGD-mimetic (small-molecule tyrosine derivative) that also reversibly blocks GP IIb/IIIa. Abciximab is a chimeric monoclonal antibody Fab fragment that irreversibly blocks the receptor for days. Eptifibatide’s short-acting, fully reversible profile makes it the ideal tool for rapid on/off platelet inhibition in mechanistic and in vivo thrombosis research.
Technical Specifications
| Property | Specification |
|---|---|
| Product Name | Eptifibatide (Glycoprotein IIb/IIIa Inhibitor) — Research Grade (RUO) |
| Catalog Number (SKU) | UPOR-EPT-188627-80-7 |
| CAS Number | 188627-80-7 |
| Molecular Formula | C₃₅H₄₉N₁₁O₉S₂ |
| Molecular Weight | 831.96 g/mol |
| Peptide Sequence | Mpr–Har–Gly–Asp–Trp–Pro–Cys–NH₂ (cyclic; Har = homoarginine) |
| Peptide Class | Synthetic cyclic heptapeptide |
| Recognition Motif | KGD (Lys-Gly-Asp) — mimics fibrinogen RGD sequence |
| Disulfide Bonds | 1 intramolecular; mercaptopropionyl (Mpr) residue forms the cyclic structure |
| Origin | Derived from barbourin, a disintegrin from Sistrurus miliarius barbouri (pigmy rattlesnake) venom |
| Mechanism | Reversible glycoprotein IIb/IIIa (αIIbβ3 integrin) antagonist — inhibits platelet aggregation |
| Purity (HPLC) | ≥98.0% |
| Peptide Content | ≥90% |
| Appearance | White to off-white lyophilized powder |
| Solubility | Freely soluble in water and aqueous buffers (PBS); soluble in DMSO |
| Endotoxin | ≤1.0 EU/mg |
| Water Content | ≤5.0% |
| Counter-ion | Acetate |
| pH | 4.5 – 6.5 (1% aqueous solution) |
| Heavy Metals | ≤10 ppm |
| Storage | -20°C, protected from light and moisture |
| Grade | Research Grade (RUO) |
| Reference Context | Active principle of FDA-approved Integrilin (ACS/PCI) — for research reference use |
| Applications | Platelet aggregation, thrombosis, GP IIb/IIIa integrin pharmacology, ACS models |
| Certifications | ISO 9001, cGMP, FDA facility registration |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg vials |
| Shelf Life | 2 years (stored at -20°C) |
| Disclaimer | Research Use Only (RUO) — not for human diagnostic or therapeutic use |
Key Benefits — Eptifibatide
Reversible GP IIb/IIIa Receptor Antagonism
Direct, reversible antagonism of the platelet glycoprotein IIb/IIIa (αIIbβ3 integrin) receptor. Blocks the final common pathway of platelet aggregation with rapid onset and offset, enabling precise on/off control in platelet function and thrombosis assays.
Reversible AntagonistKGD-Motif Fibrinogen Blockade
The KGD (Lys-Gly-Asp) motif mimics the RGD sequence of fibrinogen, competitively blocking fibrinogen and von Willebrand factor cross-linking of adjacent platelets. Barbourin-derived sequence with engineered receptor specificity.
KGD MotifCyclic Disulfide-Stabilized Scaffold
A single intramolecular disulfide bond linking the mercaptopropionyl (Mpr) residue to Cys forms a rigid cyclic heptapeptide scaffold, conferring proteolytic stability and conformational integrity compared to linear KGD peptides.
Cyclic Scaffold≥98% HPLC Purity Research Peptide
≥98% HPLC purity with peptide content ≥90% and endotoxin ≤1.0 EU/mg. White to off-white lyophilized powder supplied with full analytical documentation (COA, HPLC, MS) for reproducible research-grade studies.
≥98% HPLCApplications
Platelet Aggregation & Thrombosis Research
Light transmission aggregometry, platelet-rich plasma assays, and in vitro thrombosis models. Reference antiplatelet for dose-response and reversibility studies.
GP IIb/IIIa / αIIbβ3 Integrin Pharmacology
Ligand-binding, receptor occupancy, and competitive inhibition studies targeting the platelet αIIbβ3 integrin and its fibrinogen/vWF ligands.
Acute Coronary Syndrome Models
Preclinical ACS and PCI models, reperfusion studies, and stent thrombosis research using the Integrilin active principle as a reference GP IIb/IIIa inhibitor.
Hemostasis & Coagulation Studies
Platelet function analysis in hemostasis, bleeding-time, and coagulation cascade research requiring precise, reversible platelet inhibition.
Disintegrin & Venom-Peptide Research
Structure-function studies of disintegrins from Sistrurus miliarius barbouri venom and KGD/RGD motif recognition by integrin receptors.
Peptide Reference Standard & Assay Development
Quantitative reference standard for HPLC/MS method development, bioanalytical assay validation, and cyclic peptide stability studies.
Frequently Asked Questions
Eptifibatide (CAS 188627-80-7) is a synthetic cyclic heptapeptide glycoprotein IIb/IIIa (αIIbβ3 integrin) inhibitor based on the KGD (Lys-Gly-Asp) motif of barbourin, a disintegrin from pigmy rattlesnake venom. It works by mimicking the RGD sequence of fibrinogen — the KGD motif competes for the GP IIb/IIIa binding site, blocking fibrinogen and von Willebrand factor cross-linking of platelets and thereby inhibiting platelet aggregation, the final common pathway of thrombus formation. Unlike abciximab, eptifibatide is a reversible, short-acting antagonist.
They represent the three structural classes of GP IIb/IIIa inhibitors. Eptifibatide is a cyclic KGD-motif heptapeptide; tirofiban is a non-peptide RGD-mimetic small molecule; and abciximab is a chimeric monoclonal antibody Fab fragment. Eptifibatide and tirofiban are short-acting and reversible (platelet function recovers within hours), while abciximab binds irreversibly for days. This makes eptifibatide ideal for rapid on/off platelet inhibition studies.
Primary applications include platelet aggregation and thrombosis research, GP IIb/IIIa / αIIbβ3 integrin pharmacology, and acute coronary syndrome (ACS) models. It is also used in hemostasis and coagulation studies, disintegrin/venom-peptide structure-function research, and as a peptide reference standard for assay development.
Store the lyophilized powder at -20°C, protected from light and moisture, for up to 2 years. For reconstitution, dissolve in sterile water or PBS to the desired concentration; the peptide is freely soluble in aqueous buffers. Avoid repeated freeze-thaw cycles — aliquot the reconstituted solution and store single-use aliquots at -20°C to preserve biological activity and prevent aggregation.
Every shipment includes a Certificate of Analysis (COA) (HPLC purity ≥98.0%, peptide content, endotoxin ≤1.0 EU/mg, water content, heavy metals), MSDS, HPLC chromatogram, and mass spectrometry (MS) data confirming molecular weight and sequence. UPOR Biotech operates under ISO 9001, cGMP, and FDA facility registration. All products are supplied for Research Use Only (RUO) — not for human diagnostic or therapeutic use.